Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Group 1 - The company held its 20th meeting of the 11th Board of Directors on November 6, 2025, with all 9 directors present, including independent directors attending via remote voting [1][3][4] - The meeting approved the proposal regarding the resignation and re-election of an independent director, with a unanimous vote of 9 in favor [3][5] - The company plans to hold its second extraordinary general meeting of shareholders on November 24, 2025, at 14:00 [4][5] Group 2 - The independent director Liang Biming submitted his resignation on November 5, 2025, due to personal reasons, and will continue to fulfill his duties until a new independent director is elected [77][78] - Zhang Chunying has been nominated as the candidate for the independent director position, recommended by the largest shareholder, Dunhua Jincheng Industrial Co., Ltd., which holds 27.35% of the company's shares [78][79] - The independent director candidate must pass the qualification and independence review by the Shenzhen Stock Exchange before the shareholders' meeting can vote on the proposal [79] Group 3 - The company ensures that the notice for the extraordinary general meeting complies with relevant laws and regulations, including the Company Law and the Shenzhen Stock Exchange rules [83] - The meeting will adopt a combination of on-site and online voting methods, with specific voting times outlined [84][86] - Shareholders must register to attend the meeting, with detailed registration procedures provided [93][94]

Core Viewpoint - Jilin Aodong has announced the nomination of Ms. Zhang Chunying as an independent director candidate for the company's 11th Board of Directors [2] Company Summary - Jilin Aodong has made a formal announcement regarding the nomination of a new independent director [2]

关于独立董事离任暨补选独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业股份有限公司（以下简称"公司"）于 2025 年 11 月 6 日召开 第十一届董事会第二十次会议审议通过了《关于独立董事离任暨补选独立董事的 议案》。现将相关事项公告如下： 一、独立董事离任情况 公司董事会于 2025 年 11 月 5 日收到独立董事梁毕明先生递交的书面辞呈。 梁毕明先生因个人原因，提请辞去公司第十一届董事会独立董事、董事会审计委 员会主任委员职务及提名委员会委员职务，辞职后不在公司及控股子公司任职。 梁毕明先生的原定任职期间为 2023 年 7 月 17 日至 2026 年 7 月 16 日。截至 本公告披露日，梁毕明先生未持有公司股份，不存在未履行完毕的公开承诺。 为保障公司董事会工作的正常开展，确保公司董事人数以及独立董事人数 符合《上市公司独立董事管理办法》《公司章程》等有关规定，梁毕明先生离任 将自公司股东会选举产生新任独立董事后生效。在此期间，独立董事梁毕明先生 仍继续履行独立董事及董事会专门委员会的相应职责。 梁毕明先生在公司任职 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-062 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 吉林敖东药业集团股份有限公司 独立董事提名人声明与承诺 提名人敦化市金诚实业有限责任公司现就提名张春颖女士为吉林敖东药业 集团股份有限公司第十一届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为吉林敖东药业集团股份有限公司第十一届董事会独立董事候选人（参 见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名 人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交 易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-061 吉林敖东药业集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第二十次会议决 议召开公司 2025 年第二次临时股东会（以下简称"本次股东会"），本次股东会采用现场 投票和网络投票相结合的表决方式，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：经公司第十一届董事会第二十次会议审议通过，决定召 开公司 2025 年第二次临时股东会，本次会议的召集、召开符合《中华人民共和国公司法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 24 日 14:00 （2）网络投票时间：通过深圳证券交易所系 ...

证券代码：000623 证券简称：吉林敖东 公告编号:2025-059 二、董事会会议审议情况 1、审议《关于独立董事离任暨补选独立董事的议案》 吉林敖东药业集团股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第二十次会议通知以书面方式于 2025 年 11 月 3 日发出。 2、会议于 2025 年 11 月 6 日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生、肖维维女士、梁毕明先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理人员列席本次董事会 会议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 三、备查文件 1、公司第十一届董事会第二十次会议决议； 表决结果：通过。同意票 9 票，反对票 0 票，弃权票 0 票。 全文详见公司于 2025 年 11 月 7 日 ...

Core Viewpoint - Jilin Aodong's stock price has shown fluctuations with a year-to-date increase of 27.06%, while recent trading indicates a slight decline over the past five days [1] Financial Performance - For the period from January to September 2025, Jilin Aodong reported revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while net profit attributable to shareholders reached 2.26 billion yuan, reflecting a significant increase of 81.70% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Jilin Aodong was 61,200, a decrease of 7.18% from the previous period, with an average of 19,456 circulating shares per shareholder, which is an increase of 7.73% [2] Dividend Distribution - Since its A-share listing, Jilin Aodong has distributed a total of 4.664 billion yuan in dividends, with 1.881 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, the Southern CSI 500 ETF held 13.93 million shares, a decrease of 317,900 shares from the previous period, while the Hong Kong Central Clearing Limited held 11.82 million shares, down by 319,620 shares [3]

Core Insights - The report highlights that 44 brokerage firms have invested in 351 stocks, with a total holding value exceeding 66 billion yuan as of the end of Q3 [2][3] - High-end manufacturing and technology sectors are identified as popular investment directions for brokerages, reflecting a shift towards structural opportunities in the equity market [2][3] Brokerage Holdings Overview - The top 10 stocks held by brokerages by market value include Muyuan Foods, Guangqi Technology, and Cangge Mining, with holdings exceeding 1 billion yuan for several stocks [3][4] - The distribution of holdings indicates a strong focus on sectors such as machinery, pharmaceuticals, electronics, and basic chemicals, with the highest number of stocks in machinery equipment (35 stocks) and pharmaceuticals (28 stocks) [3][4] Trading Activity - Brokerages have entered 186 new stocks, with notable new positions including Postal Savings Bank and China Foreign Transport, each exceeding 30 million shares [4] - A total of 69 stocks saw increased holdings, particularly in the basic chemicals and transportation sectors, while 61 stocks were reduced, indicating a selective approach to portfolio management [5][4] Self-Operated Business Performance - Self-operated business remains the largest revenue contributor for brokerages, with a reported income of 186.857 billion yuan in the first three quarters, marking a 43.83% year-on-year increase [6][7] - Major brokerages like CITIC Securities and Guotai Junan reported significant growth in self-operated income, driven by a recovering equity market and strategic asset allocation [6][7] Market Trends and Analysis - Analysts note that the active trading environment and increased margin financing have positively impacted brokerage performance, with a significant rise in average daily trading volume [7] - The shift towards equity assets and the reduction in bond investments reflect a broader trend of rebalancing within the brokerage sector [7]

Core Viewpoint - The article highlights the latest holdings of securities firms in the A-share market as of the end of Q3 2025, indicating significant investment activity and sector preferences among these firms [1][5]. Holdings Overview - As of the end of Q3 2025, 44 securities firms appeared in the top ten shareholders of 361 listed companies, with a total holding value of 66.623 billion yuan [1]. - The most concentrated sectors for securities firm investments are hardware equipment and chemical industries, with 41 and 33 stocks respectively, followed by pharmaceuticals and machinery with 26 and 20 stocks [1]. Major Holdings - The top holdings by securities firms include: - CITIC Securities holds 1.3743 million shares of Muyuan Foods valued at 1.984 billion yuan [4]. - Shenwan Hongyuan has a holding of 1.2148 million shares of Guangqi Technology valued at 1.079 billion yuan [4]. - Other notable holdings include Cangge Mining and Jilin Aodong, with holdings valued at 928 million yuan and 865 million yuan respectively [2][4]. New Investments - In Q3, securities firms entered the top ten shareholders of 206 new stocks, primarily in the non-ferrous metals, pharmaceuticals, hardware equipment, and chemical sectors [5]. - Noteworthy new investments include: - Guotai Junan's entry into Postal Savings Bank with a holding valued at 727 million yuan [5]. - CITIC Securities' new position in Huayuan Ecology valued at 344 million yuan [5]. Increased Holdings - A total of 63 stocks saw increased holdings from securities firms in Q3, with significant increases in positions such as: - Dongfang Securities increased its holding in Inner Mongolia Huadian by 21.94 million shares, adding over 8.8 million yuan in value [5]. - CITIC Securities increased its position in Muyuan Foods by 507,500 shares, adding approximately 433 million yuan [5]. Decreased Holdings - Some securities firms reduced their holdings in certain stocks, such as CITIC Securities reducing its position in Xin Nuo Wei, while others like Shenwan Hongyuan reduced holdings in Guangqi Technology and Cangge Mining but saw their holding values increase due to stock price appreciation [6]. Self-operated Business Performance - The performance of securities firms' self-operated businesses is closely linked to their stock holdings, with total self-operated income reaching 186.857 billion yuan in the first three quarters of the year, accounting for over 44% of total revenue [7]. - CITIC Securities led with a self-operated income of 31.603 billion yuan, a year-on-year increase of approximately 46% [8]. Self-operated Business Breakdown - The self-operated income of major securities firms for the first three quarters includes: - CITIC Securities: 31.603 billion yuan, 45.88% year-on-year growth [8]. - Guotai Junan: 20.37 billion yuan, 90.11% year-on-year growth [8]. - Other firms like China Galaxy and Shenwan Hongyuan also reported significant self-operated income exceeding 10 billion yuan [8].